The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease

A. H. Dabholkar; C. Han; M. M. Paris; M. C. Perez; S. N. Atkinson; D. A. Peura

首页> 外文期刊>Alimentary Pharmacology & Therapeutics >The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease

【24h】

The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease

机译：带有双重延迟释放制剂的质子泵抑制剂右兰索拉唑在胃食管反流病患者中的12个月安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aliment Pharmacol Ther 2011; 33: 366–377

机译：Aliment Pharmacol Ther 2011； 33：366–377

著录项

来源
《Alimentary Pharmacology & Therapeutics》 |2011年第3期|366-377|共12页
作者
A. H. Dabholkar; C. Han; M. M. Paris; M. C. Perez; S. N. Atkinson; D. A. Peura;
展开▼
作者单位

Research Development Takeda Global Research Development Center Inc. Deerfield IL USA.;

Division of Gastroenterology Hepatology University of Virginia Health Sciences Center Charlottesville VA USA.;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. [J] . Dabholkar AH, Han C, Paris MM, Alimentary pharmacology & therapeutics. . 2011,第3期

机译：具有双重延迟释放制剂的质子泵抑制剂右兰索拉唑在胃食管反流病患者中的12个月安全性。
2. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. [J] . Peura DA, Metz DC, Dabholkar AH Alimentary pharmacology & therapeutics. . 2009,第10期

机译：具有新型双重延迟释放制剂的质子泵抑制剂右兰索拉唑MR的安全性：全球临床试验经验。
3. Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre Studies [J] . Majid Vakily, Ronald D. Lee, Jingtao Wu, Clinical drug investigation . 2009,第1期

机译：药物相互作用与Dexlansoprazole改良释放（TAK-390MR），质子泵抑制剂具有双重延迟释放的四个随机，双盲，交叉，安慰剂对照，单中心研究的结果
4. Soft Capsule as Gastrointestinal Reflux Resistant Delivery System: Concept Delayed Release Profiles of GRAS Dietary Supplements [C] . N. Chidambaram, M. W. Price Controlled Release Society Annual Meeting and Exposition . 2007

机译：软胶囊作为胃肠道回流防护系统：GRAS膳食补充剂的概念和延迟释放曲线
5. Characterization of Esophageal Hypervigilance in a Cohort of Gastroesophageal Reflux Disease Proton-Pump Inhibitor Non-Responders [D] . Guadagnoli, Livia Anna. 2020

机译：食糖回流型疾病群体泵抑制剂非响应者食管血管性诱导的表征
6. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region [O] . Khean Lee Goh, Myung Gyu Choi, Ping I Hsu, 2016

机译：地兰索拉唑的药理和安全性概况：新型质子泵抑制剂–对亚太地区食管反流疾病的治疗意义
7. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease [O] . A. H. Dabholkar, C. Han, M. M. Paris, 2010

机译：Dexlansopazole的12个月安全性曲线，一种具有双延迟释放制剂的质子泵抑制剂，胃肠道反流患者患者

The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease

摘要

著录项

相似文献

相关主题

期刊订阅